1/42
Comprehensive vocabulary flashcards reviewing essential cardiovascular, endocrine, renal, and antithrombotic pharmacologic mechanisms, molecular targets, and adverse effects.
ApoB-100
The structural apolipoprotein present on VLDL, IDL, and LDL particles that acts as the primary ligand binding hepatic LDL receptors (LDLR) to facilitate receptor-mediated endocytosis and plasma LDL clearance.
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
A regulatory protein that binds cell-surface LDL receptors and diverts them toward lysosomal degradation rather than endosomal recycling, thereby decreasing surface receptor density and increasing circulating LDL concentrations.
Familial Hypercholesterolemia (FH)
An inherited disorder caused by impaired LDLR function, defective ApoB binding, or PCSK9 gain of function, resulting in markedly diminished LDL clearance, lifelong elevated circulating LDL, and premature coronary artery disease.
Atorvastatin
A competitive inhibitor of hepatic HMG-CoA reductase that decreases intracellular mevalonate and cholesterol synthesis, triggering compensatory upregulation of surface LDLR expression to enhance the clearance of circulating LDL.
Ezetimibe
An antilipemic drug that inhibits the intestinal NPC1L1 transporter, reducing dietary and biliary cholesterol absorption to deplete liver cholesterol stores and promote LDLR-mediated plasma clearance.
Evolocumab (Repatha)
A monoclonal antibody that binds circulating PCSK9 to prevent PCSK9-mediated LDLR degradation, thereby preserving LDL receptor recycling to the hepatocyte surface and significantly lowering plasma LDL.
Obicetrapib
An emerging inhibitor of cholesteryl ester transfer protein (CETP) that alters the bidirectional transfer of cholesteryl esters and triglycerides between HDL and ApoB-containing lipoproteins.
Hydrochlorothiazide
A thiazide diuretic that blocks the NCC cotransporter in the distal convoluted tubule (DCT), causing initial natriuresis and volume contraction followed by long-term reductions in systemic vascular resistance (SVR), while increasing distal sodium delivery to drive potassium wasting.
Furosemide
A loop diuretic that inhibits the NKCC2 cotransporter in the thick ascending limb of the loop of Henle, producing potent natriuresis, diuresis, and preload reduction while dissipating the lumen-positive potential to increase urinary excretion of K+, Ca2+, and Mg2+.
Spironolactone
A competitive antagonist of intracellular mineralocorticoid receptors in collecting-duct principal cells that decreases aldosterone-mediated ENaC and Na+/K+-ATPase activity, promoting potassium retention and antiandrogenic effects.
Captopril
An angiotensin-converting enzyme (ACE) inhibitor that blocks the generation of angiotensin II and slows bradykinin degradation, leading to vasodilation, reduced aldosterone secretion, potential hyperkalemia, and a characteristic dry cough.
Valsartan
An angiotensin receptor blocker (ARB) that selectively blocks vascular and adrenal AT1 receptors to inhibit angiotensin II-driven vasoconstriction and aldosterone release without causing bradykinin accumulation.
Sacubitril/valsartan
A combination medication combining a neprilysin inhibitor (sacubitril) to preserve endogenous natriuretic peptides with an ARB (valsartan) to block AT1 receptors; used in heart failure and contraindicated with concurrent ACE inhibitors.
Metoprolol
A cardioselective β1-adrenergic receptor blocker that lowers heart rate, myocardial contractility, and juxtaglomerular renin secretion to decrease blood pressure and myocardial oxygen consumption.
Nifedipine
A dihydropyridine (DHP) calcium-channel blocker that selectively antagonizes vascular L-type Ca2+ channels, causing arteriolar relaxation and decreased SVR, commonly accompanied by peripheral edema and reflex tachycardia.
Diltiazem
A non-dihydropyridine calcium-channel blocker that inhibits cardiac, nodal, and vascular L-type Ca2+ channels to reduce heart rate, AV nodal conduction, and myocardial contractility; avoided in HFrEF due to negative inotropy.
KATP Channel (Pancreatic Beta Cell)
An ATP-sensitive potassium channel composed of Kir6.2 and SUR1 subunits that closes in response to a high intracellular ATP/ADP ratio, triggering plasma membrane depolarization, calcium influx, and insulin granule exocytosis.
Metformin
A biguanide antihyperglycemic that inhibits mitochondrial complex I, activates AMP-activated protein kinase (AMPK), and downregulates lipogenic and gluconeogenic enzymes to suppress excessive hepatic glucose output without stimulating insulin secretion.
Tolbutamide
A sulfonylurea that binds the SUR1 subunit of beta-cell KATP channels to force channel closure, stimulating membrane depolarization, voltage-gated calcium entry, and insulin release independently of prevailing glucose levels.
Sitagliptin
An oral dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the enzymatic degradation of endogenous incretins (GLP-1 and GIP), thereby prolonging glucose-dependent insulin augmentation and suppressing postprandial glucagon.
Semaglutide
A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that promotes glucose-dependent insulin release, suppresses excess glucagon secretion, delays gastric emptying, and enhances central satiety.
Tirzepatide
A dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that provides synergistic glycemic control and substantial body weight reduction through dual incretin signaling.
Empagliflozin
A sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks proximal tubular glucose reabsorption to produce glycosuria, osmotic diuresis, and cardiovascular/renal protection, with risks of volume depletion and euglycemic DKA.
Combined Estrogen/Progestin Contraception
A hormonal regimen combining ethinyl estradiol with a progestin (such as norethindrone or levonorgestrel) that suppresses hypothalamic GnRH and pituitary gonadotropins, elevates hepatic SHBG, thickens cervical mucus, and opposes endometrial hyperplasia.
Leuprolide
A synthetic GnRH receptor agonist whose continuous (non-pulsatile) administration elicits a brief initial flare of gonadotropin release followed by extensive GnRH receptor desensitization, downregulating LH, FSH, and gonadal sex steroids.
Bromocriptine
A dopamine D2 receptor agonist that directly inhibits anterior pituitary lactotroph prolactin secretion, alleviating hyperprolactinemia-induced suppression of hypothalamic GnRH release.
Raloxifene
A selective estrogen receptor modulator (SERM) that displays estrogen-agonist activity in bone tissue to reduce osteoclast resorption and vertebral fracture risk while acting as an estrogen antagonist in breast tissue; it increases venous thromboembolism risk and does not alleviate hot flashes.
Thyroid Peroxidase (TPO)
An apical follicular enzyme that utilizes hydrogen peroxide to oxidize trapped iodide, iodinate tyrosyl residues on thyroglobulin (organification), and couple MIT and DIT residues into stored T3 and T4.
Organification
The covalent incorporation of oxidized iodine into tyrosyl residues of thyroglobulin, generating monoiodotyrosine (MIT) and diiodotyrosine (DIT) intermediates during thyroid hormone synthesis.
Levothyroxine
Synthetic thyroxine (T4) that replaces deficient endogenous hormone and serves as a prohormone substrate for peripheral outer-ring deiodinases to generate active triiodothyronine (T3).
Methimazole
A thionamide antithyroid drug that inhibits thyroid peroxidase (TPO)-dependent oxidation, organification, and coupling, halting de novo thyroid hormone synthesis without immediately destroying existing colloid-stored hormone.
Propylthiouracil (PTU)
A thionamide antithyroid medication that inhibits TPO-mediated intrathyroidal hormone synthesis and additionally blocks peripheral deiodinase conversion of T4 to active T3.
Alendronate
A nitrogen-containing bisphosphonate that binds hydroxyapatite crystals at bone surfaces and is internalized by resorbing osteoclasts to inhibit farnesyl pyrophosphate synthase, suppressing osteoclast-mediated bone breakdown.
Parathyroid Hormone (PTH)
A peptide hormone secreted by parathyroid chief cells in response to low ionized calcium sensing by CaSR; it promotes renal calcium reabsorption, stimulates 1-alpha-hydroxylase to generate calcitriol, induces renal phosphate wasting, and stimulates osteoclast resorption during sustained exposure.
Dual Antiplatelet Therapy (DAPT)
The coadministration of aspirin (blocking COX-1 and TXA2) and a P2Y12 receptor antagonist (blocking ADP signaling) to inhibit complementary positive-feedback loops of platelet activation and protect against stent thrombosis.
Aspirin
An antiplatelet agent that irreversibly acetylates and inhibits platelet cyclooxygenase-1 (COX-1), permanently suppressing thromboxane A2 (TXA2) generation for the circulating lifespan of the platelet.
Clopidogrel
An oral thienopyridine prodrug requiring CYP2C19 hepatic biotransformation to an active metabolite that irreversibly blocks the platelet P2Y12 ADP receptor, inhibiting downstream activation of glycoprotein IIb/IIIa.
Tirofiban
An intravenous antiplatelet agent that reversibly blocks the platelet glycoprotein IIb/IIIa (αIIbβ3) receptor, directly impeding the final common aggregation pathway of fibrinogen-mediated cross-linking.
Unfractionated Heparin (UFH)
A fast-acting parenteral anticoagulant that binds antithrombin via a high-affinity pentasaccharide sequence and forms a molecular ternary bridge with thrombin (IIa) and factor Xa to markedly accelerate their catalytic inactivation.
Warfarin
An oral vitamin K antagonist that inhibits vitamin K epoxide reductase (VKORC1), preventing the post-translational gamma-carboxylation of clotting factors II, VII, IX, and X as well as natural anticoagulant proteins C and S.
Apixaban
An oral direct factor Xa inhibitor that binds directly to the catalytic active site of free and clot-associated factor Xa, attenuating prothrombinase complex activity and thrombin generation without requiring an antithrombin cofactor.
Alteplase (tPA)
A recombinant tissue plasminogen activator fibrinolytic agent that converts fibrin-bound plasminogen into active plasmin, leading to enzymic degradation of the cross-linked fibrin meshwork within an established occlusive thrombus.
Nitroglycerin
An antianginal organic nitrate that undergoes intracellular denitration to release nitric oxide (NO), stimulating soluble guanylyl cyclase to elevate cyclic GMP and cause venodilation, which lowers cardiac preload and ventricular wall tension.